Literature DB >> 22067657

Effects of conditional depletion of topoisomerase II on cell cycle progression in mammalian cells.

Ruth E Gonzalez1, Chang-Uk Lim, Kelly Cole, Christine Hanko Bianchini, Gary P Schools, Brian E Davis, Ikuo Wada, Igor B Roninson, Eugenia V Broude.   

Abstract

Topoisomerase II (Topo II) that decatenates newly synthesized DNA is targeted by many anticancer drugs. Some of these drugs stabilize intermediate complexes of DNA with Topo II and others act as catalytic inhibitors of Topo II. Simultaneous depletion of Topo IIα and Topo IIβ, the two isoforms of mammalian Topo II, prevents cell growth and normal mitosis, but the role of Topo II in other phases of mammalian cell cycle has not yet been elucidated. We have developed a derivative of p53-suppressed human cells with constitutive depletion of Topo IIβ and doxycycline-regulated conditional depletion of Topo IIα. The effects of Topo II depletion on cell cycle progression were analyzed by time-lapse video microscopy, pulse-chase flow cytometry and mitotic morphology. Topo II depletion increased the duration of the cell cycle and mitosis, interfered with chromosome condensation and sister chromatid segregation and led to frequent failure of cell division, ending in either cell death or restitution of polyploid cells. Topo II depletion did not change the rate of DNA replication but increased the duration of G 2. These results define the effects of decreased Topo II activity, rather than intermediate complex stabilization, on the mammalian cell cycle.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22067657      PMCID: PMC3356834          DOI: 10.4161/cc.10.20.17778

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  38 in total

1.  Premitotic chromosome individualization in mammalian cells depends on topoisomerase II activity.

Authors:  J F Giménez-Abián; D J Clarke; J Devlin; M I Giménez-Abián; C De la Torre; R T Johnson; A M Mullinger; C S Downes
Journal:  Chromosoma       Date:  2000-07       Impact factor: 4.316

2.  Conditional suppression of cellular genes: lentivirus vector-mediated drug-inducible RNA interference.

Authors:  Maciej Wiznerowicz; Didier Trono
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

3.  Functional compatibility between isoform alpha and beta of type II DNA topoisomerase.

Authors:  Ayako Sakaguchi; Akihiko Kikuchi
Journal:  J Cell Sci       Date:  2004-03-01       Impact factor: 5.285

4.  Topoisomerase II poisoning by ICRF-193.

Authors:  K C Huang; H Gao; E F Yamasaki; D R Grabowski; S Liu; L L Shen; K K Chan; R Ganapathi; R M Snapka
Journal:  J Biol Chem       Date:  2001-09-27       Impact factor: 5.157

5.  G2 DNA damage checkpoint inhibition and antimitotic activity of 13-hydroxy-15-oxozoapatlin.

Authors:  N T Rundle; L Xu; R J Andersen; M Roberge
Journal:  J Biol Chem       Date:  2001-09-25       Impact factor: 5.157

6.  A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference.

Authors:  Douglas A Rubinson; Christopher P Dillon; Adam V Kwiatkowski; Claudia Sievers; Lili Yang; Johnny Kopinja; Dina L Rooney; Mingdi Zhang; Melanie M Ihrig; Michael T McManus; Frank B Gertler; Martin L Scott; Luk Van Parijs
Journal:  Nat Genet       Date:  2003-02-18       Impact factor: 38.330

7.  Inhibition of DNA decatenation, but not DNA damage, arrests cells at metaphase.

Authors:  Dimitrios A Skoufias; Françoise B Lacroix; Paul R Andreassen; Leslie Wilson; Robert L Margolis
Journal:  Mol Cell       Date:  2004-09-24       Impact factor: 17.970

Review 8.  Catalytic topoisomerase II inhibitors in cancer therapy.

Authors:  Annette K Larsen; Alexandre E Escargueil; Andrzej Skladanowski
Journal:  Pharmacol Ther       Date:  2003-08       Impact factor: 12.310

9.  Homologous recombination repair is essential for repair of vosaroxin-induced DNA double-strand breaks.

Authors:  Rachael Elizabeth Hawtin; David Elliot Stockett; Oi Kwan Wong; Cecilia Lundin; Thomas Helleday; Judith Ann Fox
Journal:  Oncotarget       Date:  2010-11

10.  Topoisomerase II and histone deacetylase inhibitors delay the G2/M transition by triggering the p38 MAPK checkpoint pathway.

Authors:  Alexei Mikhailov; Mio Shinohara; Conly L Rieder
Journal:  J Cell Biol       Date:  2004-08-09       Impact factor: 10.539

View more
  21 in total

Review 1.  Human RECQL5: guarding the crossroads of DNA replication and transcription and providing backup capability.

Authors:  Venkateswarlu Popuri; Takashi Tadokoro; Deborah L Croteau; Vilhelm A Bohr
Journal:  Crit Rev Biochem Mol Biol       Date:  2013-04-29       Impact factor: 8.250

2.  Lasonolide A, a potent and reversible inducer of chromosome condensation.

Authors:  Yong-Wei Zhang; Arun K Ghosh; Yves Pommier
Journal:  Cell Cycle       Date:  2012-11-16       Impact factor: 4.534

3.  Mitotic chromosomes are compacted laterally by KIF4 and condensin and axially by topoisomerase IIα.

Authors:  Kumiko Samejima; Itaru Samejima; Paola Vagnarelli; Hiromi Ogawa; Giulia Vargiu; David A Kelly; Flavia de Lima Alves; Alastair Kerr; Lydia C Green; Damien F Hudson; Shinya Ohta; Carol A Cooke; Christine J Farr; Juri Rappsilber; William C Earnshaw
Journal:  J Cell Biol       Date:  2012-11-19       Impact factor: 10.539

Review 4.  Roles of eukaryotic topoisomerases in transcription, replication and genomic stability.

Authors:  Yves Pommier; Yilun Sun; Shar-Yin N Huang; John L Nitiss
Journal:  Nat Rev Mol Cell Biol       Date:  2016-09-21       Impact factor: 113.915

5.  Topoisomerase II is required for the proper separation of heterochromatic regions during Drosophila melanogaster female meiosis.

Authors:  Stacie E Hughes; R Scott Hawley
Journal:  PLoS Genet       Date:  2014-10-23       Impact factor: 5.917

6.  The analysis of mutant alleles of different strength reveals multiple functions of topoisomerase 2 in regulation of Drosophila chromosome structure.

Authors:  Valentina Mengoli; Elisabetta Bucciarelli; Ramona Lattao; Roberto Piergentili; Maurizio Gatti; Silvia Bonaccorsi
Journal:  PLoS Genet       Date:  2014-10-23       Impact factor: 5.917

7.  DDK dependent regulation of TOP2A at centromeres revealed by a chemical genetics approach.

Authors:  Kevin Z L Wu; Guan-Nan Wang; Jennifer Fitzgerald; Huong Quachthithu; Michael D Rainey; Angela Cattaneo; Angela Bachi; Corrado Santocanale
Journal:  Nucleic Acids Res       Date:  2016-07-12       Impact factor: 16.971

8.  Restoration of topoisomerase 2 function by complementation of defective monomers in Drosophila.

Authors:  Amber M Hohl; Morgan Thompson; Alexey A Soshnev; Jianhong Wu; James Morris; Tao-Shih Hsieh; C-Ting Wu; Pamela K Geyer
Journal:  Genetics       Date:  2012-08-24       Impact factor: 4.562

9.  Ciprofloxacin is a potential topoisomerase II inhibitor for the treatment of NSCLC.

Authors:  Tomasz Kloskowski; Natalia Gurtowska; Joanna Olkowska; Jakub Marcin Nowak; Jan Adamowicz; Jakub Tworkiewicz; Robert Dębski; Alina Grzanka; Tomasz Drewa
Journal:  Int J Oncol       Date:  2012-10-04       Impact factor: 5.650

10.  The α isoform of topoisomerase II is required for hypercompaction of mitotic chromosomes in human cells.

Authors:  Christine J Farr; Melissa Antoniou-Kourounioti; Michael L Mimmack; Arsen Volkov; Andrew C G Porter
Journal:  Nucleic Acids Res       Date:  2014-01-29       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.